To report the FDA approval of semaglutide 7.2 mg (Wegovy HD) specifically for weight management in adults with obesity.
Approach:
Key Findings:
Semaglutide 7.2 mg demonstrated a mean weight loss of 20.7% in adults with obesity in the STEP UP trial.
31.2% of patients achieved weight reductions of at least 25% in the same trial.
In adults with obesity and type 2 diabetes, mean weight loss was 14.1%, with 21.3% achieving reductions of at least 20% in the STEP UP T2D trial.
Safety and tolerability profile consistent with previous semaglutide studies.
Interpretation:
Wegovy HD shows significant efficacy in weight loss and is expected to address obesity-related health issues in the US, especially with the FDA's National Priority Voucher highlighting its importance.
Limitations:
Long-term effects and safety beyond the trial duration are not yet fully understood.
The trials primarily involved adults; further studies may be needed for broader populations, including different age groups and ethnicities.
Conclusion:
Wegovy HD is a promising treatment option for obesity and related conditions, with a planned launch in April 2026, which could significantly impact public health.
